Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
Conclusions and Relevance In adults with treatment-resistant depression, single doses of intranasal mebufotenin benzoate were well tolerated and produced rapid, robust, and durable reductions in depressive symptoms.
Appeared: Wednesday, October 28. JAMA. Peer-reviewed journal.